Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

When will we have a clone? An industry perspective on the typical CLD timeline

13 Mar 2024

Abstract excerpt

Cell line development (CLD) represents a complex but highly critical process during the development of a biological drug. To shed light on this crucial workflow, a team of BioPhorum members (authors) has developed and executed surveys focused on the activities and effort involved in a typical CLD campaign. An average of 27 members from different companies that participate in the BioPhorum CLD working group...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38477447
DOI: 10.1002/btpr.3449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

When will we have a clone? An industry perspective on the typical CLD timelinePMID 38477447Read ↗

Utilizing non-clonal CHO cell derived materials for preclinical studies of complex moleculesSemantic proximity Read ↗

Shortening the Biologics Clinical Timeline with a Novel Method for Generating Stable, High Producing Cell Pools and ClonesSemantic proximity Read ↗

From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal AntibodiesSemantic proximity Read ↗

Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable poolSemantic proximity Read ↗

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-CloningSemantic proximity Read ↗

High‐throughput screening of antibody‐expressing CHO clones using an automated shaken deep‐well systemSemantic proximity Read ↗

Demonstration of a robust high cell density transient CHO platform yielding mAb titers of up to 2 g/L without medium exchangeSemantic proximity Read ↗

Rapid cGMP Manufacturing of COVID-19 monoclonal antibody using stable CHO cell poolsSemantic proximity Read ↗

Development of a high cell density transient CHO platform yielding mAb titers greater than 2 g/L in only 7 daysSemantic proximity Read ↗

RNA‐Seq Highlights High Clonal Variation in Monoclonal Antibody Producing CHO CellsSemantic proximity Read ↗

High‐throughput and automation advances for accelerating single‐cell cloning, monoclonality and early phase clone screening steps in mammalian cell line development for biologics productionSemantic proximity Read ↗

The use of site-specific recombination and cassette exchange technologies for monoclonal antibody production in Chinese Hamster ovary cells: retrospective analysis and future directionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.